Moleculin Biotec Stock Price, News & Analysis

Moleculin Biotech (NASDAQ: MBRX) reported its financial results for 2022, showing a net loss of $29.0 million, up from $6.7 million in 2021. R&D expenses increased to $19.0 million, driven by heightened clinical trial activities. The company has sufficient cash, totaling $43.1 million, to fund operations into the third quarter of 2024. Recent highlights include positive data from Annamycin's trials, an 80% overall response rate for refractory AML, and Fast Track Designation from the FDA for WP1122. A conference call to discuss results will be held on March 23, 2023, at 8:30 AM ET.

Moleculin Biotech, Inc. (MBRX) announced significant updates regarding its clinical trials on March 22, 2023. The company is actively recruiting for three Phase 1b/2 trials, with one trial having recently transitioned to Phase 2. Notably, Moleculin has achieved 50% recruitment in its Phase 2 trial targeting soft tissue sarcoma (STS) lung metastases. Preliminary results from the trials indicate a 67% response rate and no cardiotoxicity associated with its lead drug, Annamycin. The company anticipates multiple data readouts and milestones throughout 2023 as it advances its pipeline for hard-to-treat cancers.

Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that its abstract for the next-generation anthracycline, Annamycin, has been accepted for presentation at the AACR Annual Meeting 2023 from April 14-19, 2023 in Orlando, FL. The presentation, titled Exploration of Annamycin Organotropism, focuses on targeting liver cancers. Annamycin has shown potential in animal models for significantly improved localization over doxorubicin and reduced cardiotoxicity, enhancing its therapeutic prospects for treating acute myeloid leukemia and soft tissue sarcoma lung metastases.

Moleculin Biotech, Inc. (Nasdaq: MBRX) will report its full year 2022 financial results on March 22, 2023, after market close. The Company is in the clinical stage, developing treatments for hard-to-treat tumors and viruses. The management will host a conference call on March 23, 2023, at 8:30 AM ET to discuss operational and financial results. Investors can access the call via phone or through a live webcast.

Moleculin Biotech, Inc. (NASDAQ: MBRX) announced its participation in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 12:40 PM ET. Jonathan P. Foster, the Chief Financial Officer, will present a live video webcast, accessible on the Company's website. This event will also allow one-on-one meetings with registered investors. Moleculin focuses on developing treatments for hard-to-treat tumors and viruses, highlighted by its lead program Annamycin for acute myeloid leukemia and soft tissue sarcoma. The Company is also advancing several other oncology and antiviral candidates.

Moleculin Biotech, Inc. (NASDAQ: MBRX) announced on March 13, 2023, that it has no exposure to Silicon Valley Bank (SVB), which has been taken over by the Federal Deposit Insurance Corp. due to liquidity issues. The company confirmed it does not hold any deposits or investments at SVB. Moleculin is a clinical stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viruses, including its lead drug Annamycin, aimed at relapsed acute myeloid leukemia and soft tissue sarcoma lung metastases. The company's pipeline includes several promising drug candidates targeting various cancers and viral infections.

Moleculin Biotech, Inc. (NASDAQ: MBRX) announced the publication of data supporting Annamycin, a non-cardiotoxic anthracycline. The research shows Annamycin's potential in treating hard-to-treat tumors. An independent review of 42 subjects indicated no cardiotoxicity, distinguishing Annamycin from traditional anthracyclines like doxorubicin. Key modifications to Annamycin have enhanced its efficacy against multidrug-resistant tumors. Annamycin is currently being evaluated for soft tissue sarcoma and acute myelogenous leukemia. The manuscript, titled ‘Anthracycline-induced cardiotoxicity – are we about to clear this hurdle?’ was published in the European Journal of Cancer.

Moleculin Biotech, Inc. (NASDAQ: MBRX) announced the treatment of the first subject in Italy as part of its Phase 1/2 trial, MB-106, evaluating Annamycin combined with Cytarabine for refractory acute myeloid leukemia (AML). The Phase 1/2 trial builds on earlier successful trials, with the MB-105 study showing an 80% overall response rate. Annamycin is designed to avoid cardiotoxicity and demonstrate higher efficacy against chemotherapy-resistant cancers. The company aims to expand recruitment and has received Fast Track and Orphan Drug Designation from the FDA for Annamycin. The final clinical study report is expected to be published soon.

Moleculin Biotech, Inc. (MBRX) announced positive topline results from its MB-105 Phase 1 trial assessing Annamycin for treating relapsed or refractory acute myeloid leukemia (AML). The trial showcased an 80% overall response rate (ORR) in patients aged 60 and above, with no reported cardiotoxicity. The median number of prior therapies was four, indicating a challenging patient population. The company is optimistic about Annamycin, especially given its encouraging preliminary efficacy data and safety profile. Annamycin is also in ongoing combination trials with Cytarabine, aiming for further indications in AML treatment.